Home › Autosomal Dominant Polycystic Kidney › NCT04630613

NOX4 and Related Biomarkers in ADPKD

NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease

Who can join

Ages 15 to 40 · All sexes

Inclusion Criteria:

* ADPKD (based on Ravine et al. criteria)
* Class 1 A-E according to imaging classification
* Male and female subjects 15 - 40 years of age
* Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI)
* Ability to provide written, informed consent

Exclusion Criteria:

* Class 2 according to imaging classification
* Concomitant systemic disease affecting the kidney
* Diabetes mellitus
* Predicted urine protein excretion in \>1 g/24 hrs
* Use of antioxidants i.e. vitamins, Nrf2 activators
* Abnormal urinalysis

About the study

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Sponsor: Mayo Clinic · Participants: 60 · Started: Jul 21, 2020

Contact the study team

Official record on ClinicalTrials.gov — NCT04630613

Locations in the U.S.

Conditions

• Autosomal Dominant Polycystic Kidney

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.